Wegovy is being considered for public funding in New Zealand to address severe obesity cases.
The drug uses semaglutide to regulate appetite and has shown significant clinical weight-loss results.
Experts emphasize that obesity in New Zealand is linked to systemic environmental issues like food swamps.
Long-term success requires addressing root social causes alongside clinical pharmaceutical interventions.